Continuous GIP Infusion Explored with Semaglutide for Enhanced Glycemic Control in Type 2 Diabetes
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
Abstract
A 6-week randomized trial investigated continuous native GIP infusion, alone or with semaglutide, for glycemic control in type 2 diabetes. 61 participants were enrolled.